ASH Clinical News ACN_6.4s_SUPP_full_issue | Page 36
The outlook
for patients with multiple myeloma
is still unfolding.
Development in the
anti-CD38 class
needs to continue.
Multiple myeloma remains incurable despite
recent therapeutic advances. There’s still a
significant need for new treatment options.
At Sanofi Genzyme, we’re working to ensure
patients can look ahead with newfound hope.
Their fi ght is our fi ght.
See what’s unfolding at
CommittedtoMM.com
www.sanofi genzyme.com
© 2019 sanofi -aventis U.S. LLC. All rights reserved.
SAUS.ONP.19.04.2258